ASLN

ASLAN Pharmaceuticals Limited [ASLN] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ASLN Stock Summary

In the News

ASLN Financial details

Company Rating
-
Market Cap
8.34M
Income
-44.22M
Revenue
12M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
34
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-0.24
Forward P/E
-
PEG
0.09
P/S
0.87
P/B
-12.27
P/C
-
P/FCF
-1.68
Quick Ratio
1.95
Current Ratio
2.11
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.74
EPS next Y
-
EPS next Q
-
EPS this Y
-26.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.99%
Revenue last 5Y
31.95%
Revenue Q/Q
-
EPS Q/Q
39.29%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-101%
ROE
-761%
ROC
-1.87%
Gross Margin
100%
Oper. Margin
-369%
Profit Margin
-377%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.392-4.69
52W High
-
52W Low
-
RSI
-
Rel Volume
0.75
Avg Volume
1.02M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.467
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
CMC.DE
NVDA
AAPL
LLY.DE
3V64.DE
Same Sector
VLNS.TO
PCIB.OL
PROG
PRVA
GNOW
Check Those
CFOO
LGBT
GFSA3.SA
4563.T
Similar Market Cap
FTLB
BMMJ
MRIT.L
TNXP
FLRM.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 1.02M
  • Market Capitalization 8.34M
  • Employee 34
  • CEO Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.
  • Headquarters Singapore,SG
  • IPO Date 2018-05-04
  • Website https://aslanpharma.com

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.